Kazuyoshi Ohkawa

4.3k total citations
158 papers, 2.4k citations indexed

About

Kazuyoshi Ohkawa is a scholar working on Oncology, Hepatology and Epidemiology. According to data from OpenAlex, Kazuyoshi Ohkawa has authored 158 papers receiving a total of 2.4k indexed citations (citations by other indexed papers that have themselves been cited), including 74 papers in Oncology, 70 papers in Hepatology and 62 papers in Epidemiology. Recurrent topics in Kazuyoshi Ohkawa's work include Pancreatic and Hepatic Oncology Research (46 papers), Hepatitis C virus research (37 papers) and Hepatocellular Carcinoma Treatment and Prognosis (34 papers). Kazuyoshi Ohkawa is often cited by papers focused on Pancreatic and Hepatic Oncology Research (46 papers), Hepatitis C virus research (37 papers) and Hepatocellular Carcinoma Treatment and Prognosis (34 papers). Kazuyoshi Ohkawa collaborates with scholars based in Japan, United States and China. Kazuyoshi Ohkawa's co-authors include Norio Hayashi, Tetsuo Takehara, Tomohide Tatsumi, Tatsuya Kanto, Ryotaro Sakamori, Takuya Miyagi, Akinori Kasahara, Hisashi Ishida, Naoki Hiramatsu and Yutaka Sasaki and has published in prestigious journals such as Journal of Biological Chemistry, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Kazuyoshi Ohkawa

138 papers receiving 2.3k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Kazuyoshi Ohkawa Japan 29 1.0k 798 710 618 526 158 2.4k
Hidetoshi Nitta Japan 27 757 0.8× 509 0.6× 706 1.0× 536 0.9× 315 0.6× 133 2.2k
Tom M. Ganten Germany 23 471 0.5× 452 0.6× 414 0.6× 1.1k 1.8× 467 0.9× 68 2.0k
Ian Walters United States 22 758 0.8× 347 0.4× 542 0.8× 615 1.0× 1.1k 2.0× 58 2.6k
Johann von Felden Germany 19 769 0.8× 493 0.6× 456 0.6× 679 1.1× 255 0.5× 44 1.9k
Masahiro Ohira Japan 22 502 0.5× 358 0.4× 572 0.8× 415 0.7× 561 1.1× 185 2.0k
Yasunobu Matsuda Japan 29 577 0.6× 448 0.6× 577 0.8× 919 1.5× 434 0.8× 79 2.2k
Purva Gopal United States 25 868 0.9× 979 1.2× 502 0.7× 562 0.9× 110 0.2× 92 2.3k
Takatoshi Ishiko Japan 29 964 1.0× 596 0.7× 1.3k 1.9× 1.4k 2.3× 333 0.6× 141 3.4k
Tianqiang Song China 21 1.1k 1.1× 561 0.7× 624 0.9× 549 0.9× 163 0.3× 86 2.2k
Matthew M. Yeh United States 28 921 0.9× 528 0.7× 850 1.2× 429 0.7× 190 0.4× 83 2.4k

Countries citing papers authored by Kazuyoshi Ohkawa

Since Specialization
Citations

This map shows the geographic impact of Kazuyoshi Ohkawa's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kazuyoshi Ohkawa with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kazuyoshi Ohkawa more than expected).

Fields of papers citing papers by Kazuyoshi Ohkawa

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kazuyoshi Ohkawa. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kazuyoshi Ohkawa. The network helps show where Kazuyoshi Ohkawa may publish in the future.

Co-authorship network of co-authors of Kazuyoshi Ohkawa

This figure shows the co-authorship network connecting the top 25 collaborators of Kazuyoshi Ohkawa. A scholar is included among the top collaborators of Kazuyoshi Ohkawa based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kazuyoshi Ohkawa. Kazuyoshi Ohkawa is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
3.
Nakabori, Tasuku, Kaori Mukai, Koji Konishi, et al.. (2024). Safety and Feasibility of Combining On-Demand Selective Locoregional Treatment with First-Line Atezolizumab Plus Bevacizumab for Patients with Unresectable Hepatocellular Carcinoma. Current Oncology. 31(3). 1543–1555. 3 indexed citations
4.
5.
Nakabori, Tasuku, Kei Kunimasa, Kaori Mukai, et al.. (2024). Feasibility of atezolizumab and bevacizumab combination regimens in patients with hepatocellular carcinoma and lung cancer taking direct oral anticoagulants. Cancer Medicine. 13(12). e7430–e7430. 1 indexed citations
6.
Nakabori, Tasuku, Yugo Kai, Ryoji Takada, et al.. (2024). Abscopal effect in a patient with advanced hepatocellular carcinoma upon resuming bevacizumab in combination with atezolizumab after radiotherapy. Clinical Journal of Gastroenterology. 17(6). 1053–1057. 4 indexed citations
7.
Takada, Ryoji, Kenji Ikezawa, Takuo Yamai, et al.. (2023). Parallel administration of nanoliposomal irinotecan and levo-leucovorin for pancreatic cancer. BMC Cancer. 23(1). 711–711. 2 indexed citations
8.
Ikezawa, Kenji, Yugo Kai, Ryoji Takada, et al.. (2023). Comprehensive review of pancreatic acinar cell carcinoma: epidemiology, diagnosis, molecular features and treatment. Japanese Journal of Clinical Oncology. 54(3). 271–281. 11 indexed citations
9.
Yamai, Takuo, Kenji Ikezawa, Naotoshi Sugimoto, et al.. (2023). Utility of Comprehensive Genomic Profiling Tests for Patients with Incurable Pancreatic Cancer in Clinical Practice. Cancers. 15(3). 970–970. 13 indexed citations
10.
Nakabori, Tasuku, et al.. (2023). Usefulness of on‐site cytology of liver tumor biopsy in specimen sampling for cancer genomic profiling test. Cancer Medicine. 12(7). 7888–7892. 4 indexed citations
11.
12.
Myojin, Yuta, Takahiro Kodama, Kazuki Maesaka, et al.. (2020). ST6GAL1 Is a Novel Serum Biomarker for Lenvatinib-Susceptible FGF19-Driven Hepatocellular Carcinoma. Clinical Cancer Research. 27(4). 1150–1161. 57 indexed citations
13.
Takada, Ryoji, Kazuyoshi Ohkawa, Yoji Kukita, et al.. (2020). Clinical Utility of Pancreatic Cancer Circulating Tumor DNA in Predicting Disease Progression, Prognosis, and Response to Chemotherapy. Pancreas. 49(9). e93–e95. 3 indexed citations
14.
Tahata, Yuki, Ryotaro Sakamori, Ryoko Yamada, et al.. (2019). Hepatocellular carcinoma occurrence does not differ between interferon‐based and interferon‐free treatment with liver histological assessment. Hepatology Research. 50(3). 313–320. 4 indexed citations
15.
Katayama, Kazuhiro, Mitsuru Sakakibara, Kazuho Imanaka, et al.. (2011). Effect of zinc supplementation in patients with type C liver cirrhosis. Open Journal of Gastroenterology. 1(2). 28–34. 11 indexed citations
16.
Kohga, Keisuke, Tetsuo Takehara, Tomohide Tatsumi, et al.. (2009). Anticancer Chemotherapy Inhibits MHC Class I–Related Chain A Ectodomain Shedding by Downregulating ADAM10 Expression in Hepatocellular Carcinoma. Cancer Research. 69(20). 8050–8057. 73 indexed citations
17.
Uemura, Akio, Tetsuo Takehara, Takuya Miyagi, et al.. (2009). Natural killer cell is a major producer of interferon γ that is critical for the IL-12-induced anti-tumor effect in mice. Cancer Immunology Immunotherapy. 59(3). 453–463. 25 indexed citations
18.
Ohkawa, Kazuyoshi, Tetsuo Takehara, Michio Kato, et al.. (2008). Supportive Role Played by Precore and PreS2 Genomic Changes in the Establishment of Lamivudine‐Resistant Hepatitis B Virus. The Journal of Infectious Diseases. 198(8). 1150–1158. 11 indexed citations
19.
Kohga, Keisuke, Tetsuo Takehara, Akihisa Uemura, et al.. (2007). Regulation of the NKG2D immunoreceptor by soluble mica during transcatheter arterial embolization for hepatocellular carcinoma. Hepatology. 46(4). 424–425. 1 indexed citations
20.
Kuzushita, Noriyoshi, Norio Hayashi, Tatsuya Kanto, et al.. (1999). Involvement of transporter associated with antigen processing 2 (TAP2) gene polymorphisms in hepatitis C virus infection. Gastroenterology. 116(5). 1149–1154. 31 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Hidetoshi Nitta Breakdown of academic impact, for papers by Tom M. Ganten Breakdown of academic impact, for papers by Ian Walters Breakdown of academic impact, for papers by Johann von Felden Breakdown of academic impact, for papers by Masahiro Ohira Breakdown of academic impact, for papers by Yasunobu Matsuda Breakdown of academic impact, for papers by Purva Gopal Breakdown of academic impact, for papers by Takatoshi Ishiko Breakdown of academic impact, for papers by Tianqiang Song Breakdown of academic impact, for papers by Matthew M. Yeh
Rankless by CCL
2026